Analysis of meningococcal vaccine uptake in patients with invasive meningococcal disease, Czech Republic, 2006–2022

Česká verze

Authors: P. Křížová ¹ ; Z. Okonji ^1,2; M. Honskus ^1,2
Authors place of work: Národní referenční laboratoř pro meningokokové nákazy, Centrum epidemiologie a mikrobiologie, Státní zdravotní ústav, Praha ¹; 3. lékařská fakulta Univerzity Karlovy, Praha ²
Published in the journal: Epidemiol. Mikrobiol. Imunol. 72, 2023, č. 4, s. 243-247
Category: Krátké sdělení

Summary

In 2006–2022, 958 cases of invasive meningococcal disease (IMD) were reported to the surveillance programme in the Czech Republic, of which 21 (2.19%) had a history of vaccination with one of the meningococcal vaccines. Data analysis shows that these vaccines provide a very good protection against IMD. It was found that vaccinated patients with IMD either were not vaccinated against the causative serogroup and/or did not receive a booster dose. The results of this analysis show the benefit of both vaccines available in the Czech Republic: recombinant vaccine containing meningococcal serogroup B antigens (MenB vaccine) and tetravalent conjugate vaccine containing antigens of four meningococcal serogroups A, C, W, Y (A, C, W, Y conjugate vaccine). The results also show the benefit of meningococcal vaccine booster doses and the need for giving MenB vaccine to young children as early as possible.

Zdroje

Česká vakcinologická společnost ČLS JEP. Doporučení a stanoviska [online]. 2023. Dostupné na www: https://www.vakcinace. eu/doporuceni-a-stanoviska.
Národní referenční laboratoř pro meningokokové nákazy. Vybrané publikace [online]. Dostupné na www: https://szu.cz/ odborna-centra-a-pracoviste/centrum-epidemiologie-a-mikrobiologie/oddeleni-bakterialnich-vzdusnych-nakaz/narodni-referencni-laborator-pro-meningokokove-nakazy/vybrane-publikace-nrl-pro-meningokokove-infekce/.
Křížová P, Honskus M, Okonji Z, et al. Analýza epidemiologických a molekulárních dat surveillance invazivního meningokokového onemocnění v České republice za období 1993–2020. Epidemiol Mikrobiol imunol, 2022;71(3):148–160.
McNamara LA, Topaz N, Wang X, et al. High Risk for Invasive Meningococcal Disease Among Patients Receiving Eculizumab (Soliris) Despite Receipt of Meningococcal Vaccine. MMWR Morb Mortal Wkly Rep, 2017;66(27):734–737, doi: 10.15585/mmwr. mm6627e1.
PubMLST database. Public databases for molecular typing and microbial genome diversity. Dostupné na www: https://pubmlst.org/organisms/neisseria-spp/.
Brehony C, Rodrigues CMC, Borrow R, et al. Distribution of Bexsero® Antigen Sequence Types (BASTs) in invasive meningococcal disease isolates: Implications for immunisation. Vaccine, 2016;34(39):4690–4697, doi: 10.1016/j.vaccine.2016.08.015.
Rodrigues CMC, Jolley KA, Smith A, et al. Meningococcal Deduced Vaccine Antigen Reactivity (MenDeVAR) Index: a Rapid and Accessible Tool That Exploits Genomic Data in Public Health and Clinical Microbiology Applications. J Clin Microbiol, 2020; 59(1):e02161–20, doi: 10.1128/JCM.02161-20.
Soler-Garcia A, Fernández de Sevilla M, Abad R, et al. Meningococcal Serogroup B Disease in Vaccinated Children. J Pediatric Infect Dis Soc, 2020;9(4):454–459, doi: 10.1093/jpids/piz071.
Üçkardeş D, Göknar N, Kasap N, et al. Meningococcemia in a vaccinated child receiving eculizumab and review of the literature. Turk J Pediatr, 2023;65(1):129–134, doi: 10.24953/turkjped.2022.190.
Ladhani SN, Campbell H, Amin-Chowdhury Z, et al. Timing of meningococcal vaccination with 4CMenB (Bexsero®) in children with invasive meningococcal group B (MenB) disease in England. Vaccine. 2022;40(10):1493–1498, doi: 10.1016/j.vaccine.2021.12.010.